IDEAS home Printed from https://ideas.repec.org/a/nat/nature/v596y2021i7871d10.1038_s41586-021-03681-2.html
   My bibliography  Save this article

Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans

Author

Listed:
  • Galit Alter

    (Beth Israel Deaconess Medical Center
    MIT and Harvard)

  • Jingyou Yu

    (Beth Israel Deaconess Medical Center)

  • Jinyan Liu

    (Beth Israel Deaconess Medical Center)

  • Abishek Chandrashekar

    (Beth Israel Deaconess Medical Center)

  • Erica N. Borducchi

    (Beth Israel Deaconess Medical Center)

  • Lisa H. Tostanoski

    (Beth Israel Deaconess Medical Center)

  • Katherine McMahan

    (Beth Israel Deaconess Medical Center)

  • Catherine Jacob-Dolan

    (Beth Israel Deaconess Medical Center
    Harvard Medical School)

  • David R. Martinez

    (University of North Carolina at Chapel Hill)

  • Aiquan Chang

    (Beth Israel Deaconess Medical Center
    Harvard Medical School)

  • Tochi Anioke

    (Beth Israel Deaconess Medical Center)

  • Michelle Lifton

    (Beth Israel Deaconess Medical Center)

  • Joseph Nkolola

    (Beth Israel Deaconess Medical Center)

  • Kathryn E. Stephenson

    (Beth Israel Deaconess Medical Center)

  • Caroline Atyeo

    (MIT and Harvard
    Harvard Medical School)

  • Sally Shin

    (MIT and Harvard)

  • Paul Fields

    (Adaptive Biotechnologies)

  • Ian Kaplan

    (Adaptive Biotechnologies)

  • Harlan Robins

    (Adaptive Biotechnologies)

  • Fatima Amanat

    (Icahn School of Medicine at Mount Sinai)

  • Florian Krammer

    (Icahn School of Medicine at Mount Sinai)

  • Ralph S. Baric

    (University of North Carolina at Chapel Hill)

  • Mathieu Gars

    (Janssen Vaccines & Prevention)

  • Jerald Sadoff

    (Janssen Vaccines & Prevention)

  • Anne Marit Groot

    (Janssen Vaccines & Prevention)

  • Dirk Heerwegh

    (Janssen Research & Development)

  • Frank Struyf

    (Janssen Research & Development)

  • Macaya Douoguih

    (Janssen Vaccines & Prevention)

  • Johan Hoof

    (Janssen Vaccines & Prevention)

  • Hanneke Schuitemaker

    (Janssen Vaccines & Prevention)

  • Dan H. Barouch

    (Beth Israel Deaconess Medical Center
    MIT and Harvard
    Harvard Medical School)

Abstract

The Ad26.COV2.S vaccine1–3 has demonstrated clinical efficacy against symptomatic COVID-19, including against the B.1.351 variant that is partially resistant to neutralizing antibodies1. However, the immunogenicity of this vaccine in humans against SARS-CoV-2 variants of concern remains unclear. Here we report humoral and cellular immune responses from 20 Ad26.COV2.S vaccinated individuals from the COV1001 phase I–IIa clinical trial2 against the original SARS-CoV-2 strain WA1/2020 as well as against the B.1.1.7, CAL.20C, P.1 and B.1.351 variants of concern. Ad26.COV2.S induced median pseudovirus neutralizing antibody titres that were 5.0-fold and 3.3-fold lower against the B.1.351 and P.1 variants, respectively, as compared with WA1/2020 on day 71 after vaccination. Median binding antibody titres were 2.9-fold and 2.7-fold lower against the B.1.351 and P.1 variants, respectively, as compared with WA1/2020. Antibody-dependent cellular phagocytosis, complement deposition and natural killer cell activation responses were largely preserved against the B.1.351 variant. CD8 and CD4 T cell responses, including central and effector memory responses, were comparable among the WA1/2020, B.1.1.7, B.1.351, P.1 and CAL.20C variants. These data show that neutralizing antibody responses induced by Ad26.COV2.S were reduced against the B.1.351 and P.1 variants, but functional non-neutralizing antibody responses and T cell responses were largely preserved against SARS-CoV-2 variants. These findings have implications for vaccine protection against SARS-CoV-2 variants of concern.

Suggested Citation

  • Galit Alter & Jingyou Yu & Jinyan Liu & Abishek Chandrashekar & Erica N. Borducchi & Lisa H. Tostanoski & Katherine McMahan & Catherine Jacob-Dolan & David R. Martinez & Aiquan Chang & Tochi Anioke & , 2021. "Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans," Nature, Nature, vol. 596(7871), pages 268-272, August.
    • Handle: RePEc:nat:nature:v:596:y:2021:i:7871:d:10.1038_s41586-021-03681-2
    DOI: 10.1038/s41586-021-03681-2
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41586-021-03681-2
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1038/s41586-021-03681-2?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Laura Solforosi & Lea M. M. Costes & Jeroen T. B. M. Tolboom & Katherine McMahan & Tochi Anioke & David Hope & Tetyana Murdza & Michaela Sciacca & Emily Bouffard & Julia Barrett & Cindy Wu & Nicole Ha, 2023. "Booster with Ad26.COV2.S or Omicron-adapted vaccine enhanced immunity and efficacy against SARS-CoV-2 Omicron in macaques," Nature Communications, Nature, vol. 14(1), pages 1-14, December.
    2. Caroline G. Atyeo & Lydia L. Shook & Sara Brigida & Rose M. Guzman & Stepan Demidkin & Cordelia Muir & Babatunde Akinwunmi & Arantxa Medina Baez & Maegan L. Sheehan & Erin McSweeney & Madeleine D. Bur, 2022. "Maternal immune response and placental antibody transfer after COVID-19 vaccination across trimester and platforms," Nature Communications, Nature, vol. 13(1), pages 1-15, December.
    3. Craig A. Magaret & Li Li & Allan C. deCamp & Morgane Rolland & Michal Juraska & Brian D. Williamson & James Ludwig & Cindy Molitor & David Benkeser & Alex Luedtke & Brian Simpkins & Fei Heng & Yanqing, 2024. "Quantifying how single dose Ad26.COV2.S vaccine efficacy depends on Spike sequence features," Nature Communications, Nature, vol. 15(1), pages 1-22, December.
    4. Rajeshwer S. Sankhala & Kerri G. Lal & Jaime L. Jensen & Vincent Dussupt & Letzibeth Mendez-Rivera & Hongjun Bai & Lindsay Wieczorek & Sandra V. Mayer & Michelle Zemil & Danielle A. Wagner & Samantha , 2024. "Diverse array of neutralizing antibodies elicited upon Spike Ferritin Nanoparticle vaccination in rhesus macaques," Nature Communications, Nature, vol. 15(1), pages 1-19, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:nature:v:596:y:2021:i:7871:d:10.1038_s41586-021-03681-2. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.